Jefferies Group’s Clearside Biomedical CLSD Stock Holding History

Jefferies Group’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,388	Closed	-$22K	–	2348
2018 Q4	$22K	Buy	+1,388	New	+$65.1K	﹤0.01%	2078

Other funds holding CLSD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Jefferies Group's CLSD Position: Q1 2019 in Review

Jefferies Group sold out of Clearside Biomedical (CLSD) in Q1 2019, closing a stake of 1,388 shares — an estimated $22K sold.

Jefferies Group first reported a position in CLSD in Q4 2018 and held it in 1 quarter. The position peaked at $22K in Q4 2018. 57 funds tracked by Wall St. Rank hold CLSD as of Q1 2019.

Jefferies Group reported no remaining Clearside Biomedical position as of Q1 2019 after selling out during the quarter.
Jefferies Group sold 1,388 Clearside Biomedical shares in Q1 2019, an estimated $22K.
Jefferies Group first reported a position in Clearside Biomedical in Q4 2018 and held it in 1 quarter.
Jefferies Group's Clearside Biomedical position peaked at $22K in Q4 2018.
57 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2019.

Based on Jefferies Group's 13F filing for Q1 2019, filed 15 May 2019.